Cross-disciplinary biomarkers research: Lessons learned by the CKD biomarkers consortium

Chi Yuan Hsu, Shawn Ballard, Daniel Batlle, Joseph V. Bonventre, Erwin P. Böttinger, Harold I. Feldman, Jon B. Klein, Josef Coresh, John H. Eckfeldt, Lesley A. Inker, Paul L. Kimmel, John W. Kusek, Kathleen D. Liu, Theodore E. Mifflin, Mark E. Molitch, Gary L. Nelsestuen, Casey M. Rebholz, Brad H. Rovin, Venkata S. Sabbisetti, Jennifer E. Van EykRamachandran S. Vasan, Sushrut S. Waikar, Krista M. Whitehead, Robert G. Nelson, Vasan S. Ramachandran, Joseph Bonventre, Sushrut Waikar, Venkata Sabbisetti, Jennifer Van Eyk, Qin Fu, Hermine Brunner, Vivette D’Agati, Jonathan Barasch, Josef Coresh, Casey M. Rebholz, Alan S. Go, Erwin Böttinger, Avelino Teixeira, Ilse Daehn, Mark Molitch, Daniel Batlle, Brad Rovin, Haifeng Wu, Andrew S. Levey, Lesley A. Inker, Meredith C. Foster, Chi Yuan Hsu, Kathleen Liu, Jon Klein, Michael Mauer, Gary Nelsestuen, Amy Karger, Paola Fioretto, Harold I. Feldman, Shawn Ballard, Krista Whitehead, Dawei Xie, Xiaoming Zhang, Kellie Ryan, Theodore E. Mifflin, Robert G. Nelson, Gudeta D. Fufaa, William C. Knowler, Robert L. Hanson, E. Jennifer Weil, Paul L. Kimmel, John W. Kusek, Bruce Molitoris, Michael Abrahamowicz, David Agus, Leigh Anderson, Matthew Breyer, Paul Clopton, Andrea Foulkes, Frederico Goodsaid, Stephen Hewitt, Jeffrey Kopp, Kevin Lemley, Alan Maisel, Marie Nierras, Terry M. Phillips, David Ransohoff, Andrew Rule, Steven Skates, Aliza Thompson, Elizabeth Wright

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (, a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.

Original languageEnglish (US)
Pages (from-to)894-902
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Issue number5
StatePublished - Jan 1 2015

Bibliographical note

Publisher Copyright:
© 2015 by the American Society of Nephrology.


Dive into the research topics of 'Cross-disciplinary biomarkers research: Lessons learned by the CKD biomarkers consortium'. Together they form a unique fingerprint.

Cite this